Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: BostonView who wrote (12400)	12/7/1999 12:35:00 AM
From: aknahow	Read Replies (1) \| Respond to of 17367

Thanks, I had been to the site before but never got it to produce the institutional holdings. Think you are right about the trends being nice. I continue to see XOMA as a success story rather than a failure. I am glad they have not partnered out Neuprex but would like to see them partner Mycoprex and then Neuprex after approval, if there is approval. Oh, and for all the cosmic counters, forward and back, I also admit I have been totally wrong on my view of XOMA thus far.<g>

To: BostonView who wrote (12400)	12/8/1999 8:49:00 PM
From: aknahow	Read Replies (1) \| Respond to of 17367

Scannon presents at 10 am tomorrow. iir-ny.com When at this site check the agenda.

To: BostonView who wrote (12400)	12/8/1999 9:10:00 PM
From: aknahow	Respond to of 17367

Attend Overcoming Resistance & Obtain These 9 Key Benefits 1.Find out the latest industry trends in discovery and where things are headed 2.Enhance the activity of current antibiotics and reverse antibiotic resistance with bactericidal/ permeability-increasing protein 3.Utilize metalloenzymes, a family of targets for the discovery of novel antimicrobials for combinatorial libraries 4.Learn about VITA? (Validation of In Vivo Targets) technology 5.Use functional genomic tools to identify novel targets to develop in vivo targeted antibiotics 6.Mine the MUR pathway for novel antibiotics 7.Hear a case study of daptomycin, a new lipopeptide antibiotic for gram-positive infections 8.Overcome resistance to existing microbials by inhibiting efflux pumps in pathogenic bacteria and fungi 9.Learn how the oxazolidinone mechanism of action helps to overcome resistance READ #2, again. Too bad people are going to waste money on this conference instead of just reading Yahoo for free to learn that XOMA has nothing to offer. Start your cosmic clock and count forward, XOMA dogs of any number, NOW!

To: BostonView who wrote (12400)	12/9/1999 10:57:00 AM
From: aknahow	Respond to of 17367

I was in error saying Dr Scannon was the presenter. It is as the XOMA web says and the conference web also says Dr. Steven Carroll. BTW while I think the meeting is important and am happy that XOMA is among such good company and as Larry points out the first presenter, I doubt this meeting will move the stock much. No one seems to care. Will take news on Mycoprex or trial news on hu1124 but mainly Neuprex. Overcoming Resistance: New Strategies to Develop Antibiotics and Antifungals December 9 - 10, 1999 San Diego Marriott Hotel & Marina San Diego, CA The Biotechnology Division of the Institute for International Research is pleased to bring you the "Overcoming Resistance: New Strategies to Develop Antibiotics and Antifungals" conference. This comprehensive event fully explores the issues at hand within the anti-infective marketplace, as well as providing updates in trends and technologies. You directly benefit from the expertise of leaders within the biopharmaceutical industry who provide you with realistic strategies to quickly develop effective antibiotics, antifungals and antimicrobials. Learn how to redesign your discovery platforms to include the resistance factor and get solutions on how to overcome this ever-present problem. Hear from our panel of recognized industry leaders: Angela Nilius, ABBOTT LABORATORIES John F. Barrett, BRISTOL-MYERS SQUIBB Francis Tally, CUBIST PHARMACEUTICALS George Miller, MICROCIDE PHARMACEUTICALS Joyce Sutcliffe, PFIZER Charles Gluchowski, RIBOGENE, INC. Catherine Hardalo, SCHERING-PLOUGH Joaquim Trias, VERSICOR Stephen Carroll, XOMA CORP. Kenny Wong, MERCK